Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.

Glucagon-like peptide-1 receptor agonists as neuroprotective agents for ischemic stroke: a systematic scoping review

Open access
Maskery, Mark P, Holscher, Christian, Jones, Stephanie P, Price, Christopher I, Strain, W David, Watkins, Caroline L, Werring, David J, Emsley, Hedley CA · 2021 · Journal of Cerebral Blood Flow & Metabolism

Abstract

Stroke mortality and morbidity is expected to rise. Despite considerable recent advances within acute ischemic stroke treatment, scope remains for development of widely applicable neuroprotective agents. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally licensed for the management of Type 2 Diabetes Mellitus, have demonstrated pre-clinical neuroprotective efficacy in a range of neurodegenerative conditions. This systematic scoping review reports the pre-clinical basis of GLP-1RAs as neuroprotective agents in acute ischemic stroke and their translation into clinical trials. We included 35 pre-clinical studies, 11 retrospective database studies, 7 cardiovascular outcome trials and 4 prospective clinical studies. Pre-clinical neuroprotection was demonstrated in normoglycemic models when administration was delayed by up to 24 h following stroke induction. Outcomes included reduced infarct volume, apoptosis, oxidative stress and inflammation alongside increased neurogenesis, angiogenesis and cerebral blood flow. Improved neurological function and a trend towards increased survival were also reported. Cardiovascular outcomes trials reported a significant reduction in stroke incidence with semaglutide and dulaglutide. Retrospective database studies show a trend towards neuroprotection. Prospective interventional clinical trials are on-going, but initial indicators of safety and tolerability are favourable. Ultimately, we propose that repurposing GLP-1RAs is potentially advantageous but appropriately designed trials are needed to determine clinical efficacy and cost-effectiveness.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/0271678x20952011

Cites

89 of 89 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

11 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 89 references

Research works printed but not linked: 3

  1. Zhu H, 2016, Sci Rep, 6
  2. Kang YM, 2018, Diabetes Metab J, 42
  3. Barkas F, Eur J Neurol

Cited by

See all 54

Metadata

Authors
Maskery, M. P., Holscher, C., Jones, S. P., Price, C. I., Strain, W. D., Watkins, C. L., Werring, D. J., & Emsley, H. C.
Affiliations
  • Royal Preston Hospital (GB)
  • Research and Experimental Center, Henan University of Chinese Medicine, Zhengzhou, Henan Province, China
  • University of Lancashire (GB)
  • Newcastle University (GB)
  • University of Exeter (GB)
  • National Hospital for Neurology and Neurosurgery (GB)
Corresponding author
Maskery, Mark P
Venue
Journal of Cerebral Blood Flow & Metabolism
Published
2020-09-20
Volume
41
Issue
1
Pages
14-30
ISSN
  • 0271-678X (ISSN-L)
  • 1559-7016
OpenAlex
W3087075091
Cited by
51
References
89
Citations by year
2026: 10 · 2025: 11 · 2024: 7 · 2023: 5 · 2022: 9 · 2021: 8 · 2020: 1
FWCI
0.57
Type
journal article
Language
en
Open access
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Journal of Cerebral Blood Flow & Metabolism (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Lancaster EPrints (Lancaster University) (acceptedVersion)
  • CLOK (University of Central Lancashire) (acceptedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • Royal Devon and Exeter Research Repository (Royal Devon and Exeter) (submittedVersion)
  • Newcastle University ePrints (Newcastle Univesity)
Funders
National Institute for Health and Care Research (NF-SI-0515-10116, ACF-2017-05-001)
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
  • Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
GLP-1 receptor agonists, ischemic stroke, neuroprotection, drug repurposing, semaglutide, dulaglutide, infarct size, oxidative stress, neuroinflammation, neurogenesis, angiogenesis, cerebral blood flow, stroke incidence, type 2 diabetes
MeSH terms
Glucagon-Like Peptide-1 Receptor, Ischemic Stroke, Animals, Disease Models, Animal, Humans, Prospective Studies, Retrospective Studies, Neuroprotective Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glucagon-like peptide-1 receptor agonists as neuroprotective agents for ischemic stroke: a systematic scoping review. https://app.cochat.ai/papers/10.1177/0271678x20952011
The paper
Maskery, M. P., Holscher, C., Jones, S. P., Price, C. I., Strain, W. D., Watkins, C. L., Werring, D. J., & Emsley, H. C. (2021). Glucagon-like peptide-1 receptor agonists as neuroprotective agents for ischemic stroke: a systematic scoping review. Journal of Cerebral Blood Flow & Metabolism. https://doi.org/10.1177/0271678x20952011

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.